HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 10/22/2012 -- Aegerion Pharmace (NGM:AEGR) is -1.29 - -6.16% from the previous close of $20.94. It traded between $19.1831 - 21.50 with total traded volume of 1502017 shares. At Current Market Price, AEGR is in distance of +27.05% from its 50-day Moving Average price of $15.4666 and +35.47% from its 200-day Moving Average price of $14.5049. Aegerion Pharmaceuticals Inc. (AEGR: Quote) announced after the bell Wednesday that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA determined by a vote of 13 to 2 that Aegerion has presented sufficient safety and efficacy data to support marketing of lomitapide, for the treatment of patients with Homozygous Familial Hypercholesterolemia. Aegerion Pharmaceuticals gapped open higher Thursday and climbed in early trade, before settling into a range. Shares finished up by 1.79 at $20.94 on the highest volume of the year. The stock rose to its third consecutive new high for the year.
Get The Full Research Report On AEGR For Free: CLICK HERE
Isis Pharmaceutic (NasdaqNM:ISIS) is -0.27 - -2.81% from the previous close of $9.62. It traded between $8.81 - 9.86 with total traded volume of 9860147 shares. At Current Market Price, ISIS is in distance of -30.53% from its 50-day Moving Average price of $13.4594 and -18.69% from its 200-day Moving Average price of $11.4989. ISIS Pharmaceuticals (NASDAQ: ISIS)‘s stock had its “buy” rating reaffirmed by research analysts at Needham & Company in a report released on Friday. Shares of ISIS Pharmaceuticals traded down 2.81% during mid-day trading on Friday, hitting $9.35. ISIS Pharmaceuticals has a 52 week low of $6.43 and a 52 week high of $15.61. The company’s market cap is $940.6 million. ISIS Pharmaceuticals last posted its quarterly earnings results on Monday, August 6th. The company reported ($0.01) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.08) by $0.07. The company’s quarterly revenue was up 90.7% on a year-over-year basis.
Should ISIS Breaks Its 52 Week Low : FIND HERE
James River Coal (NasdaqNM:JRCC) is +0.15 - +3.09% from the previous close of $4.85. It traded between $4.70 - 5.25 with total traded volume of 6503732 shares. Keep a close eye on JRCC, as the stock has been showing unusual moves over the past weeks. At Current market price, JRCC has recovered +197.62% from its 52-week Low of 1.68 and has Pulled back -56.60% from its 52-week high of 11.52. James River Coal Company(NASDAQ:JRCC) shares increased 6.59% to $4.85 in yesterday’s session. The 52 week trading range for the company is $1.68 – $11.52. The shares of the company dropped 49% in the last one year. The company mines engaged in processing and selling of thermal and metallurgical coal through eight active mining complexes located throughout eastern Kentucky, southern West Virginia and southern Indiana.
Can JRCC Continue To Move Higher? Find Out Here
Questcor Pharmace (NasdaqNM:QCOR) is -0.7697 - -2.99% from the previous close of $25.7597. It traded between $23.43 - 26.09 with total traded volume of 5636352 shares. Keep a close eye onQCOR, as the stock has been showing unusual moves over the past weeks. At Current market price, QCOR has recovered +44.87% from its 52-week Low of 17.25 and has Pulled back -57.58% from its 52-week high of 58.91. Questcor Pharmaceuticals, Inc.(NASDAQ:QCOR) shares climbed 1.82% to $25.76 in the previous trading session. QCOR has been downgraded by TheStreet Ratings from buy to hold. The company’s strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. Moreover, the company announced that it will release third quarter 2012 financial results on Tuesday, October 23, 2012 after the close of the U.S. financial markets. Additionally, Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who acquired Questcor Pharmaceuticals securities between April 26, 2011 and September 21, 2012.
Get Free Trend Analysis On QCOR Here
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to loose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)